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Hannah Y. Wen1✉
Metaplastic breast carcinoma (MpBC) is a rare special histologic subtype of breast carcinoma characterized by the presence of
squamous and/or mesenchymal differentiation. Most MpBCs are of triple-negative phenotype and neoadjuvant chemotherapy
(NAC) is frequently utilized in patients with MpBC. The aim of this study was to evaluate response to NAC in a retrospective cohort
of MpBCs. We identified 44 patients with MpBC treated with NAC at our center between 2002 and 2018. Median age was 48 years,
86% were clinical stage II–III, and 36% were clinically node-positive. Most (80%) MpBCs were triple-negative or low (1–10%)
hormonal receptor positive and HER2 negative on pre-NAC biopsy. While on NAC, 49% showed no clinical response or clinico-
radiological progression. Matrix-producing subtype was associated with clinico-radiological response (p= 0.0036). Post NAC, two
patients initially ineligible for breast-conserving surgery (BCS) were downstaged to be eligible for BCS, whereas three patients
potentially eligible for BCS before treatment became ineligible due to disease progression. Only one (2%) patient had a pathologic
complete response (pCR). Among the 16 patients presenting with biopsy-proven clinical node-positive disease, 3 (19%) had nodal
pCR. Axillary lymph node dissection was avoided in 3 (19%) patients who had successful axillary downstaging. Residual cancer
burden (RCB) was assessed in 22 patients and was significantly associated with disease-free survival and overall survival. We
observed a poor response or even disease progression on NAC among patients with MpBC, suggesting that NAC should be
reserved for patients with inoperable MpBC.
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INTRODUCTION
Metaplastic breast carcinoma (MpBC) is a rare special histologic
subtype of breast carcinoma, which includes a heterogeneous
group of invasive carcinomas characterized by the presence of
squamous and/or mesenchymal differentiation1. Histologic var-
iants that are recognized by the World Health Organization (WHO)
include spindle cell carcinoma, squamous cell carcinoma, and
metaplastic carcinoma with mesenchymal differentiation, which
includes matrix-producing carcinoma. Low-grade adenosquamous
carcinoma and fibromatosis-like metaplastic carcinoma are the
rare low-grade variants with a relatively favorable prognosis which
differs from the more common high-grade MpBCs2–5.
MpBC typically presents as a rapidly growing mass that is often
palpable and larger in size compared to invasive carcinoma no
special type (NST)6,7. MpBCs are usually high grade and negative
for estrogen receptor, progesterone receptor, and HER2 (i.e. of
triple-negative phenotype)6,8–10. Despite the large tumor size at
presentation, axillary lymph node involvement is infrequent, and
local recurrences and distant metastases are thought to occur by
hematogenous dissemination10,11. Patients with MpBC tend to
have worse disease-free survival and overall survival when
compared to common forms of triple-negative breast cancer
(TNBC)10,12–19.
Given the advanced stage at initial presentation and triple-
negative receptor status, neoadjuvant chemotherapy (NAC) is
often considered a treatment option for patients with MpBC.
Although rates of pathologic complete response (pCR) are
relatively high in TNBC NST, at ~30–40% with anthracycline and
taxane20,21, and over 50% with platinum22,23, the response to NAC
in MpBC has not been well studied and reported rates of pCR are
variable, ranging from 10% to 17%, with sample size ranging from
6 to 29 patients24–28. Here we sought to study the response to
NAC in patients with MpBC and clinical, radiologic, and pathologic
features that were associated with response.
RESULTS
Pre-NAC clinicopathological characteristics
From 2002 to 2018, 44 patients with MpBC treated with NAC were
identified in the institutional database. The clinicopathologic
characteristics of pre-NAC are summarized in Table 1. The median
age at diagnosis was 48 years (range: 26–77). Median clinical
tumor size was 4.1 cm (range: 2.0–11.9 cm). Forty (91%) patients
had clinical T2 or T3 tumors, and 16 (36%) had biopsy-proven
node-positive disease at presentation. Twenty-eight (64%)
patients were clinical stage II and 10 (23%) were clinical stage III.
Among the 31 patients who had genetic testing, 28 (90%) were
negative for BRCA germline mutations, 2 (6%) were BRCA1
germline mutation carriers, and 1 (3%) had BRCA2 variant of
unknown significance. The tumor histology was pure metaplastic
carcinoma in 17 (39%) patients and mixed metaplastic and
invasive carcinoma NST in 27 (61%). Histologic subtypes of
metaplastic carcinoma included matrix-producing (19; 43%),
squamous cell (12; 27%), spindle cell (6; 14%), with mixed
metaplastic elements (6; 14%), and not specified (1; 2%). No
low-grade variants of MpBC were included. Tumor-infiltrating
lymphocytes (TILs) were assessed in 31 pre-NAC biopsies with
available material for review at the time of the study. The majority
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(65%, 20/31) of the MpBCs had no TILs or low (<10%) TILs, 26% (8/
31) had intermediate (10–49%) TILs, and only 10% (3/31) of MpBCs
had high level (≥50%) of TILs. On the pre-treatment core biopsy,
30 (68%) cases were triple-negative, 12 (27%) were hormone
receptor-positive and HER2 negative, including 5 (11%) cases with
low (1–10%) hormone receptor expression, and 2 (5%) were HER2
positive. Both HER2 positive cases were matrix-producing
metaplastic carcinoma, HER2 equivocal by immunohistochemistry,
and HER2 amplification detected by fluorescence in situ
hybridization.
Chemotherapy, clinical, and radiological response and
surgical treatment
All patients received doxorubicin, cyclophosphamide, and taxol
(ACT)-based NAC regimens, including 32 (73%) patients who
received ACT alone, 9 (20%) with added platinum (carboplatin n=
8, cisplatin n= 1). One patient had disease progression while on
taxol and carboplatin and switched to carboplatin, gemcitabine,
and pembrolizumab. The two (5%) patients with HER2 amplified
MpBC received dual-anti-HER2 treatment with trastuzumab (H)
and pertuzumab (P) plus chemotherapy (ACT-HP).
Clinico-radiologic response data were available for 41 patients
(Table 2). Nearly half (49%, 20/41) of the patients had either no
clinical or radiological response (22%, 9/41) or disease progression
(27%, 11/41) while on NAC, and 51% (21/41) of patients had a
clinical or radiological response. Tumors with radiologic progres-
sion had a median increase of 2.4 cm (range 1.1–12.6 cm) in the
greatest dimension, while those with radiologic response had a
median decrease of 1.8 cm (range: 0.3–7.7 cm) in the greatest
dimension. Advanced clinical T stage (cT4) at presentation was
associated with disease progression while on NAC. A significantly
higher rate of clinico-radiologic response was seen in matrix-
producing MpBC (78%, 14/18), compared to 27% (6/22) in non-
matrix-producing MpBCs (p= 0.0036) (Table 2). Clinico-radiologic
response was observed in 25% (3/12) squamous cell carcinoma,
40% (2/5) spindle cell carcinoma and 20% (1/5) MpBC with mixed
metaplastic components. The clinicopathologic response was also
more frequent among MpBCs with intermediate-to-high levels of
TILs (8/11, 73%) compared to MpBCs with no or low TILs (9/18,
50%), but the difference did not reach statistical significance (p=
0.2732).
Most patients (77%, 34/44) underwent mastectomy post-NAC,
including 5 patients eligible for breast-conserving surgery (BCS)
who opted for a mastectomy, and 23% (10/44) had successful BCS
(Fig. 1). Two patients initially ineligible for BCS were downstaged
to eligibility for BCS post-NAC, whereas three patients potentially
eligible for BCS became ineligible due to disease progression
during treatment (Fig. 1). Twenty-two (50%) patients had sentinel
lymph node biopsy (SLNBx) only, 6 (14%) patients underwent
SLNBx and axillary lymph node dissection (ALND), and 16 (36%)
patients had ALND without SLNBx. Among the 16 patients with
node-positive disease at presentation, 5 had SLNBx and intrao-
perative evaluation after NAC, of which, 3 (19%) patients had
successful axillary downstaging and ALND was avoided.
Post-NAC pathologic evaluation
Only one patient had pCR, an overall pCR rate of 2% (1/44) in this
cohort (Table 3). The patient was a 32 years old woman with
germline BRCA1 del exons 23–24, presented with a 3 cm mass in
the right breast at 32 weeks gestation. Core biopsy revealed a
matrix-producing metaplastic carcinoma (Fig. 2), poorly differ-
entiated and of triple-negative phenotype, clinical stage II (cT2N0).
The patient started NAC with ACT after a c-section. Post-NAC
bilateral mastectomy and sentinel lymph node biopsy revealed no
residual invasive carcinoma. She remained without evidence of
disease at the last follow-up (53 months).
Table 1. Clinicopathological characteristics pre-NAC.
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Pure metaplastic carcinoma 17 (39%)
Mixed metaplastic and NST 27 (61%)
Metaplastic histologic subtype
Matrix-producing 19 (43%)
Squamous cell carcinoma 12 (27%)
Spindle cell carcinoma 6 (14%)
With mixed metaplastic elements 6 (14%)



















ACT+ platinum 9 (20%)
ACT-HP 2 (5%)
Otherb 1 (2%)
HR hormonal receptor, NST no special type, TILs tumor-infiltrating
lymphocytes, ACT doxorubicin, cyclophosphamide and taxol, ACT-HP
doxorubicin, cyclophosphamide and taxol, plus trastuzumab and pertuzu-
mab.
aFour patients had history of ipsilateral breast carcinoma, s/p breast
conserving surgery, with ipsilateral breast tumor recurrence, one patient
with stage IV disease at presentation.
bTaxol/carboplatin, then carboplatin/gemcitabine/pembrolizumab.
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One patient had a pCR in the breast but had residual metastatic
disease in one lymph node (Table 3). Among the 16 patients with
biopsy-proven nodal involvement pre-NAC, 3 (19%) patients had
nodal pCR post-NAC (Table 3).
The median residual pathologic tumor size was 2.5 cm (range: a
few cells—24.8 cm). Eighteen (41%) patients had axillary lymph
node involvement post NAC with a median number of 2 (range
1–16) positive lymph nodes. Sixteen (36%) patients had macro-
metastases, one (2%) patient had micrometastasis, and one (2%)
patient had isolated tumor cells. The median tumor bed area was
9.6 cm2 (range: 1.7–81.0 cm2). Among the 22 patients with slides
available for residual cancer cellularity assessment, the median
overall cancer cellularity was 55% (range: 0–95%). RCB was
assessed in 21 patients with residual tumor, one (5%) patient was
RCB class I, 17 (81%) patients were class II, and 3 (14%) patients
were class III.
Receptor status post-NAC was available in 38 cases, all were
triple-negative (34/38, 89%) or hormonal receptor low (1–10%)
positive and HER2 negative (4/38, 11%). Receptor status between
pre- and post-NAC was concordant in 66% (25/38) and discordant
in 34% (13/38) of patients. The most common receptor conversion
was from hormonal receptor low positive (1–10%) to negative (5/
38, 13%), followed by hormonal receptor-positive to negative (4/
38, 11%), positive to low positive (2/38, 5%), and negative to low
positive (2/38, 5%). Targeted sequencing by MSK-IMPACT29,30 was
performed in 7 patients, on pre-NAC samples in 2 patients, post-
NAC in 2 patients, pre- and post-NAC in 1 patient, and distant
metastasis in 2 patients. Recurrent somatic mutations observed
included TP53 (7/7), PTEN (3/7), PIK3R1 (2/7), and SOX17 (2/7).
Somatic mutations affecting PI3K pathway genes (PTEN, PIK3R1,
INPP4B) were detected in 71% (5/7) of cases.
Outcome analysis
Follow-up information was available for 39 patients, with a median
follow-up of 34.9 months (range: 1.6–140.4). Thirteen patients
developed distant metastases. The 3-year disease-free survival and
overall survivals were 58% and 65%, respectively. Residual cancer
burden (RCB) was the only factor associated with disease-free
survival by log-rank test (p= 0.0001) (Table 4). On univariate
analysis, post-NAC tumor size ≤ 2 cm (p= 0.046), post-NAC nodal
status (p= 0.037), and RCB (p= 0.0007) were associated with
overall survival (Table 4). Multivariate analysis was not performed
due to the small sample size and missing data for RCB in a subset
of patients.
DISCUSSION
MpBC is usually of triple-negative phenotype and appears more
aggressive than conventional TNBC. The National Comprehensive
Cancer Network (NCCN) clinical practice guidelines do not have
specific treatment recommendations for MpBC distinct from that
for invasive breast carcinoma in general31. NAC has become
Table 2. Clinicopathological characteristics in 41 patients with clinical












50 48 51 0.8159
Clinical stage
I 0 1 (11%) 0 1
II 14 (67%) 7 (78%) 4 (36%)
III 5 (24%) 0 5 (45%)
Other 2 (10%) 1 (11%) 2 (18%)
Tumor type
Pure MpBC 8 (38%) 4 (44%) 5 (45%) 0.7557
Mixed MpBC/
NST
13 (62%) 5 (56%) 6 (55%)
Metaplastic histologic subtype
MpBC—MP 14 (67%) 2 (22%) 2 (18%) 0.0036
MpBC—SCC 3 (14%) 3 (33%) 6 (55%)
MpBC—SPC 2 (10%) 1 (11%) 2 (18%)
MpBC—
mixed
1 (5%) 3 (33%) 1 (9%)
No data 1 (5%) 0 0
Tumor grade
II 6 (29%) 0 1 (9%) 0.0918
III 13 (62%) 8 (89%) 8 (73%)
No data 2 (10%) 1 (11%) 2 (18%)
TILs
<10% 9 (43%) 6 (67%) 3 (27%) 0.2732
10–49% 6 (29%) 0 2 (18%)
≥50% 2 (10%) 0 1 (9%)
No data 4 (19%) 3 (33%) 5 (45%)
MpBC metaplstic breast carcinoma, MP matrix producing, NST no special
type, SCC squamous cell carcinoma, SPC spindle cell carcinoma, TILs tumor-
infiltrating lymphocytes.
Fig. 1 Flow chart of surgical treatment. MpBC metaplastic breast cancer, NAC neoadjuvant chemotherapy, BCS breast conversing surgery.
*Patient’s choice.
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standard practice for patients with clinical stage II–III TNBCs.
However, in this study, we observed a poor response to NAC in
patients with MpBC, with only one patient achieving pCR, 22% of
the patients exhibited no clinical and radiological response, and
27% with progression while on NAC, in contrast to the 30–50%
pCR rate in TNBC reported in the literature20–23.
Benefits of NAC include downstaging the primary tumor to
allow BCS and downstaging the axilla to avoid axillary dissection
in patients presenting with node-positive disease. In our study,
only two patients were sufficiently downstaged from ineligible to
eligible for BCS post-NAC, and three patients progressed from
eligible to ineligible for BCS during treatment.
Prior studies from our institution demonstrated nodal pCR rates
of 41–48% in patients with cT1–3 biopsy-proven N1 breast cancer
treated with NAC32,33. Similarly, in the ACOSOG Z1071 trial, of the
694 patients with biopsy-proven node-positive breast cancer
(cT0–4 N1–2 M0), the nodal pCR rate was 41%34. The nodal pCR
rate in patients with TNBC in the ACOSOG Z1071 trial was 49%
(84/170)34. In contrast, in the current study, among 16 MpBC
patients with clinically node-positive disease at presentation, only
19% (3/16) had nodal pCR, a significantly lower rate than that in
patients with TNBC in the ACOSOG Z1071 trial (p= 0.0199).
Several prior studies have reported responses to NAC in MpBC.
Han et al. reported a 17% pCR rate among 29 patients with MpBC
treated with NAC25. Al-Hilli et al. reported an 11% pCR rate in 18
patients with MpBC26. Cimino-Mathews et al. reported six MpBC
patients treated with NAC, with one patient (16%) achieved pCR24.
The differences in rates of pCR across published studies may be
due to the very small sample size in some and the heterogeneous
morphology of MpBC. There are no consensus criteria that
differentiate metaplastic carcinoma from invasive ductal carci-
noma with metaplastic features1. Lack of consensus inclusion
criteria among studies may contribute to sample heterogeneity
and differences in pCR rates. In the study by Han et al., any case
showing an unequivocal metaplastic tumor component was
included in the study25. Of the 29 patients with MpBC treated
with NAC, 15 (52%) had mixed metaplastic carcinoma and invasive
carcinoma NST, including 9 (31%) patients in which the invasive
carcinoma NST was the predominant component25. Similarly, the
study by Cimino-Mathews et al. included cases with any degree of
metaplastic element24. Whereas in our study, we included only
cases with predominant metaplastic component, following the
WHO classification guidelines1, potentially accounting for the
lower response rates we observed.
Although the overall response rates in our study were low,
differences in response based on histology were observed. The
matrix-producing subtype was significantly associated with
clinical-radiologic response. Of the 18 patients with matrix-
producing subtype and with clinic-radiologic response assess-
ment, 14 (78%) patients had a response to NAC, compared to 27%
in non-matrix-producing MpBCs (p= 0.0036). The only patient
with pCR had a matrix-producing MpBC. Han et al. also reported
that matrix-producing subtype was significantly associated with
pCR in their study cohort25.
The presence of tumor-infiltrating lymphocytes (TILs) is an
independent predictor of response to NAC35,36. Denkert et al.
reported a pCR rate of over 40% in lymphocyte-predominant
breast cancer (LPBC), defined as breast cancer with more than
60% of TILs35. TNBC has the highest incidence of LPBC36,37. In a
systematic review, a median of 20% (range 4–37%, n= 1620
patients) of patients with TNBC demonstrated LPBC, defined as at
least 50% or 60% TILs37. MpBCs, however, are less frequently
associated with high levels of TILs. In one study, a high level of
TILs, defined as ≥60% of TILs, was observed in 33% of squamous
cell carcinoma but none of the matrix-producing MpBC or spindle
cell carcinomas38. In our study, high levels of TILs (≥50%) were
only seen in 10% (3/31) of MpBCs, including 2 of 10 squamous cell
carcinomas and 1 of 13 matrix-producing MpBC with TILs
assessment in pre-NAC core biopsy.
Whole-exome sequencing of MpBCs demonstrated a repertoire
of somatic mutations distinct from that of TNBC NST39. Although
both MpBC and TNBC NST harbor frequent TP53 mutations at
similar rates, MpBCs more frequently harbored mutations in
PIK3CA (29%), PIK3R1 (11%), ARID1A (11%), FAT1 (11%), and PTEN
(11%) in comparison to TNBC NST39. When compared to TNBC
NST, MpBCs were more frequently associated with mutations in
the PI3K/AKT/mTOR pathway (57% vs. 22%) and the Wnt pathway
(51% vs. 28%)39. The difference in somatic mutations may
contribute to the poor clinical outcomes in MpBC. A sequencing
analysis in the neoadjuvant GeparSepto trial showed a signifi-
cantly reduced pCR rate in PIK3CA-mutated breast cancer
compared with PIK3CA wild-type breast cancer (23% vs. 38.8%,
p < 0.0001)40. In our study cohort, sequencing analysis was only
performed in a subset of patients (n= 7), but among these
patients, 71% (5/7) had somatic mutations affecting genes in the
PI3K pathway.
Our study has several limitations. It is a retrospective study with
the possibility of selection bias. Due to the rarity of MpBC, our
sample size is limited. Data analysis was further restricted to
patients with complete data in the report or with slides retrievable
for review. Despite these limitations, our study is the largest series
of MpBC treated with NAC with detailed clinicopathologic
annotation.
In conclusion, MpBC had a poor response to conventional NAC.
Only one (2%) patient achieved a pathological complete response
in our cohort, and 27% had disease progression during NAC. The
poor response to NAC in patients with MpBC raises the question of
the utility of conventional NAC for these patients. While overall a
low rate of clinicoradiologic and pathologic response, variation in
response to NAC exists based on the histologic subtype, with
some clinical benefit from NAC observed in matrix-producing
MpBC, illustrating the heterogeneity within MpBC.
METHODS
Patient cohort
Patients with MpBC treated with NAC at our center from 2002 to 2018
were retrospectively reviewed. Clinical and radiological features were
obtained from the electronic medical record. Clinico-radiologic
Table 3. Rates of pathologic complete response in breast and lymph node stratified by histologic subtype of metaplastic carcinoma.
Metaplastic histologic subtype Overall pCR (ypT0N0) n (%) Breast pCR (ypT0) n (%) Total ypN0 n (%) Nodal pCR in cN +n (%)
All cases 1/44 (2%) 2/44 (5%) 26/44 (59%) 3/16 (19%)
Matrix-producing 1/19 (5%) 2/19 (11%) 13/19 (68%) 2/7 (29%)
Squamous cell carcinoma 0/12 0/12 5/12 (42%) 1/6 (17%)
Spindle cell carcinoma 0/6 0/6 5/6 (83%) 0/0
With mixed metaplastic elements 0/6 0/6 2/6 (33%) 0/3
No data 0/1 0/1 1/1 (100%) 0/0
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response was determined by a change in size between pre-NAC and
post-NAC on physical examination and/or radiological imaging by the
same imaging modality. Clinical lymph node status was determined by
physical examination and imaging study, confirmed with fine-needle
aspiration or core needle biopsy prior to NAC. Clinical follow-up post-
surgical treatment and recurrence events were recorded, and disease-
free survival and overall survival were evaluated. This study was
approved by the institutional review board of Memorial Sloan Kettering
Cancer Center (protocol #17-287). A waiver of consent was granted by
the institutional ethics committee because this work involves no more
than minimal risk to the participants or their privacy.
Pathologic evaluation
Pathologic characteristics were retrieved from the pathology report and
central slide review. Available diagnostic slides were reviewed by two
breast pathologists (W.W. and H.W.) to confirm diagnoses and histologic
features. A diagnosis of MpBC was rendered if metaplastic features were
predominant in the tumor. The extent of TILs was assessed on pre-NAC
biopsy according to the recommendations by the international TILs
working group41. Pathologic evaluation post-NAC followed the recom-
mendations of the international working group42. Pathological com-
plete response (pCR) was defined as no evidence of invasive disease in
the breast and lymph nodes, with or without residual ductal carcinoma
in situ (ypT0/pTis ypN0). RCB was determined from the primary tumor
bed area, overall cancer cellularity, percentage of cancer that is in situ
disease, number of positive lymph nodes, and diameter of largest
metastasis in lymph nodes, using the MD Anderson RCB calculator43.
Estrogen receptor, progesterone receptor, and HER2 assessment
followed the ASCO/CAP guidelines44,45 and were recorded in both the
pre-NAC biopsy and the post-NAC surgical specimens. Next-generation
sequencing data using MSK-IMPACT were recorded when available29,30.
Statistics
Fisher’s Exact test was used to evaluate associations between categorical
variables and response to therapy. Survival outcomes were analyzed with
the Kaplan–Meier method and statistical significance were determined by
log-rank test. A p value < 0.05 was considered statistically significant.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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